Denosumab discontinuation: COVID-19 pandemic and beyond-Reference-Cited by-同舟云学术

Denosumab discontinuation: COVID-19 pandemic and beyond

Published:2024-04-02 Issue:7 Volume:8 Page:
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:

Author:

Minisola Salvatore¹²^ORCID

Affiliation:

1. Department of Clinical , Internal, Anaesthesiologic and Cardiovascular Sciences,

2. “Sapienza” University of Rome , Internal, Anaesthesiologic and Cardiovascular Sciences,

Abstract

Abstract The coronavirus disease 2019 (COVID-19) pandemic triggered significant disruptions in health care systems around the world, with a particularly heavy impact on patients with chronic diseases. A number of studies have shown an immediate decrease in on-time denosumab therapy at the start of COVID-19 pandemic. However, independent of the “emergency” that occurred during the COVID-19 pandemic, there are other situations in which denosumab is discontinued. In such situations, it is important to have a programmed strategy to optimize care while limiting the risk for unwanted outcomes.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jbmrplus/advance-article-pdf/doi/10.1093/jbmrpl/ziae046/57140231/ziae046.pdf

Reference10 articles.

1. Impact of COVID-19 pandemic on adherence to chronic therapies: a systematic review;Olmastroni;Int J Environ Res Public Health,2023

2. On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal;Rzepka;J Bone Miner Res Plus

3. COVID pandemic and denosumab adherence;Minisola;Osteoporosis Int,2022

4. COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine;De Vincentis;J Endocrinol Investig,2022

5. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial;Miller;Bone,2008